Compare Recursion Pharmaceuticals Inc (RXRX) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Ulta Beauty Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.86B), while Ulta Beauty Inc trades at $542.26 (market cap $24.12B). The key difference: Ulta Beauty Inc is far larger — about 13× Recursion Pharmaceuticals Inc's market cap, and Ulta Beauty Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | ULTA | |
|---|---|---|
Market Cap | $1.86B | $24.12B |
Sector | Health | Consumer Cyclical |
52-Week High | $6.79 | $706.82 |
52-Week Low | $2.84 | $450.75 |
Enterprise Value | $1.38B | $26.43B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
ULTA Beauty trades at $549.23, down 2.64% today, amid mixed signals. The stock shows a bullish technical trend with strong moving averages, while fundamentals reveal steady revenue growth to $11.30B in 2025, though net income margin has softened to 9.34%. Recent Q2 2026 earnings beat expectations, and the company raised full-year guidance, yet some segments like cosmetics showed flat performance.
The outlook is cautiously optimistic, with a consensus price target of $653.14 implying significant upside. Key opportunities include digital growth and AI integration potential, but risks involve competitive pressures and reliance on discretionary consumer spending. Analyst sentiment remains predominantly bullish, supporting a favorable risk-reward profile for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
